Recovering scientist turned early stage VC A biotech optimist fighting gravity

Caravans of Biotech Immigrant Executives
April 5, 2018

Recently there’s been talk of a caravan of immigrants marching towards the United States, principally focused on Mexico and Central America.  But there’s also another caravan, this one at work in the biopharma business: the long term migration of science

Leave a comment

Two Really Big Fish That Got Away
March 23, 2018

Like all avid fly fishermen, I can recount many stories about the big ones that got away. The same goes for my experience in venture capital… as I’ve certainly missed some big ones. With the acquisition of Juno Therapeutics by

Leave a comment

Just a Little Patience: In-licensing from Biopharma
March 20, 2018

This blog was written by Samantha Truex, an Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. People who know me well will agree that patience is not one of my personal virtues.  That said, I recognize

Leave a comment

Beyond the CEO: Building An Effective Leadership Team  
March 15, 2018

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC.   The biotech twittersphere recently engaged in very thoughtful debate (resulting in a great piece by

Leave a comment

Allostery: Realizing The Promise
March 5, 2018

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and

Leave a comment

Celebrating Rare Disease Day
February 28, 2018

Today we recognize and celebrate #RareDiseaseDay to raise awareness of rare diseases and their impact on patients’ lives. Nearly 1 out of 10 Americans lives with a rare disease – more than 30M people in the United States.  NORD has documented over

Leave a comment

Grey Hair In the C-Suite: Experience, Age, And IPOs In Biotech
February 26, 2018

Biotech venture investors often prefer to back executives and entrepreneurs with a bit of grey hair. Seasoned industry veterans that possess leadership charisma along with years of experience, and the oft-accompanying learned judgement, are highly sought-after in biopharma’s seemingly endless

Leave a comment

Two’s Company, Three’s Diversity
February 12, 2018

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Two years ago, Bloomberg Business published a feature entitled At Biotech Party, Gender Diversity Means Cocktail Waitresses. Within three

3 Comments

Bringing The Human Element Full Circle Thru Adaptive Ski Coaching
February 8, 2018

My experience as an adaptive ski coach has been nothing short of life-changing. I don’t say that with hyperbole. By bringing together my passion for the mountains with my profession as an investor in biomedical therapies, adaptive coaching completes the

Leave a comment

When Does Digital Health Become Just Healthcare?
February 7, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In 2015 I went to both the JPMorgan and CES conferences, back to back, and attended numerous can’t-miss dinners,

1 Comment

We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases
February 1, 2018

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the

1 Comment

So, Your Board Asked For A Deal This Year?
January 30, 2018

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. A fresh Q1 is underway, your meetings at JPMorgan were top notch, and you have a

1 Comment